Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Dusa Pharmaceuticals abandons Levulan PDT
Wilmington, Mass. - Dusa Pharmaceuticals has stopped developing Levulan photo dynamic therapy for acne, after mid-stage trials failed to show statistically significant results.
Wilmington, Mass.
- Dusa Pharmaceuticals has stopped developing Levulan photo dynamic therapy for acne, after mid-stage trials failed to show statistically significant results, Reuters reports.
The treatment combination, called Levulan PDT, is approved for the treatment of actinic keratoses of the face and scalp. It is also used off-label to treat photodamage.
Related Videos
Related Content
